- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Nucleocapsid protein.
Displaying page 1 of 1.
EudraCT Number: 2021-000281-15 | Sponsor Protocol Number: mRNA-1273-P204 | Start Date*: 2023-09-19 |
Sponsor Name:ModernaTX, Inc. | ||
Full Title: A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and ... | ||
Medical condition: Coronavirus Disease 2019 | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-000300-38 | Sponsor Protocol Number: 001610 | Start Date*: 2021-02-05 |
Sponsor Name:Antwerp University Hospital | ||
Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE) | ||
Medical condition: Onco-hematological patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000461-33 | Sponsor Protocol Number: P2020_312 | Start Date*: 2021-02-17 |
Sponsor Name:Hopital Erasme, Université Libre de Bruxelles | ||
Full Title: Covid-19: Sars-Cov2 vaccination in hemodialysis patient: a phase IV study of the immunogenicity and its determinants | ||
Medical condition: Chronic hemodialysis patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000412-28 | Sponsor Protocol Number: P2020_284 | Start Date*: 2021-02-17 |
Sponsor Name:Hopital Erasme, Université Libre de Bruxelles | ||
Full Title: COVID-19: Sars-Cov2 vaccination in kidney transplant patient: a phase IV study of the immunogenicity and its determinants | ||
Medical condition: Kidney transplant patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002927-39 | Sponsor Protocol Number: BOOST_TX/RESCUE_TX | Start Date*: 2021-06-13 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C... | ||
Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2023-000382-14 | Sponsor Protocol Number: mRNA-1273-P203 | Start Date*: 2023-12-29 |
Sponsor Name:ModernaTX, Inc. | ||
Full Title: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of... | ||
Medical condition: Coronavirus Disease 2019 | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-006832-24 | Sponsor Protocol Number: Z-2021005 | Start Date*: 2022-01-21 |
Sponsor Name:Ziekenhuis Oost-Limburg A.V. | ||
Full Title: Heterogeneity, durability and efficacy of the humoral immune response against SARS-CoV-2 (Covid-19) after hospital-wide vaccination | ||
Medical condition: efficiency and durability of the humoral immune response after vaccination against SARS-CoV-2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004123-16 | Sponsor Protocol Number: 2019nCoV-302 | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Novavax, Inc. | |||||||||||||
Full Title: A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ ... | |||||||||||||
Medical condition: Prevention of COVID-19 caused by SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000673-83 | Sponsor Protocol Number: TJB2101 | Start Date*: 2021-03-11 |
Sponsor Name:CHU de Liège | ||
Full Title: Impact of the immune system on response to COVID-19 vaccine in allogeneic stem cell recipients | ||
Medical condition: Allogeneic hematopoietic stem cell recipients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003452-14 | Sponsor Protocol Number: SBC007C401 | Start Date*: 2023-05-02 | |||||||||||
Sponsor Name:Berlin Cures GmbH | |||||||||||||
Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability... | |||||||||||||
Medical condition: long Covid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) AT (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003998-22 | Sponsor Protocol Number: CV-NCOV-004 | Start Date*: 2020-12-16 | |||||||||||
Sponsor Name:CureVac AG | |||||||||||||
Full Title: COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 1... | |||||||||||||
Medical condition: Vaccination for prophylaxis of COVID-19 (healthy adults) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000724-35 | Sponsor Protocol Number: 216912 | Start Date*: 2021-05-11 | ||||||||||||||||
Sponsor Name:Vir Biotechnology, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Partici... | ||||||||||||||||||
Medical condition: Non-Hospitalized Participants with Mild to Moderate Coronavirus Disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
